Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:COSNASDAQ:FABCVE:IGXNASDAQ:PMN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/AFABFirst Trust Multi Cap Value AlphaDEX Fund$79.660.0%$79.23$64.89▼$82.62$155.34M1.225,517 shs441 shsIGXIntelGenx TechnologiesC$0.58+1.8%C$0.58C$0.17▼C$0.85C$87.32MN/A56,279 shs11,848 shsPMNProMIS Neurosciences$1.95-4.9%$2.04$0.95▼$8.95$36.98M0.6738,692 shs3,356 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFABFirst Trust Multi Cap Value AlphaDEX Fund+0.75%+2.89%-0.93%+4.79%+15.13%IGXIntelGenx Technologies0.00%0.00%0.00%0.00%0.00%PMNProMIS Neurosciences-0.49%+3.02%+3.54%+4.06%-67.65%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.9008 of 5 stars3.54.00.00.03.11.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOSCanadian Oil Sands3.00BuyC$0.52∞ UpsideFABFirst Trust Multi Cap Value AlphaDEX Fund0.00N/A$87.439.75% UpsideIGXIntelGenx TechnologiesN/AN/AN/AN/APMNProMIS Neurosciences3.00Buy$8.00310.17% UpsideCurrent Analyst RatingsLatest IGX, FAB, IMM, PMN, and COS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024COSCanadian Oil SandsFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$0.52(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AN/AN/AN/AIGXIntelGenx TechnologiesC$1.75M49.95C$0.08 per share7.16C$0.05 per share12.89PMNProMIS Neurosciences$10K3,697.96N/AN/A$0.20 per share9.75Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOSCanadian Oil SandsN/AN/A0.00N/AN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/A11.74∞N/AN/AN/AN/AN/AIGXIntelGenx TechnologiesN/A-C$0.08N/A∞N/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)Latest IGX, FAB, IMM, PMN, and COS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOSCanadian Oil SandsN/AN/AN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX Fund$1.481.86%N/AN/AN/AIGXIntelGenx TechnologiesN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ALatest IGX, FAB, IMM, PMN, and COS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/20/2024FABFirst Trust Multi Cap Value AlphaDEX FundQuarterly$0.24303/21/20243/22/20243/28/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOSCanadian Oil SandsN/AN/AN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AN/AN/AIGXIntelGenx Technologies164.622.772.69PMNProMIS NeurosciencesN/A1.461.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOSCanadian Oil SandsN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AIGXIntelGenx TechnologiesN/APMNProMIS Neurosciences50.13%Insider OwnershipCompanyInsider OwnershipCOSCanadian Oil SandsN/AFABFirst Trust Multi Cap Value AlphaDEX FundN/AIGXIntelGenx TechnologiesN/APMNProMIS Neurosciences10.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOSCanadian Oil Sands147,000N/AN/ANot OptionableFABFirst Trust Multi Cap Value AlphaDEX Fund147,0001.95 millionN/ANot OptionableIGXIntelGenx Technologies48150.55 millionN/ANot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableIGX, FAB, IMM, PMN, and COS HeadlinesSourceHeadlineProMIS Neurosciences (PMN) Price Target Increased by 9.38% to 8.93msn.com - April 17 at 9:02 AMProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALSglobenewswire.com - April 9 at 7:00 AMProMIS Neurosciences to Present in Upcoming Investor Conferences in Aprilglobenewswire.com - April 4 at 7:00 AMProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlightsglobenewswire.com - April 1 at 4:15 PMProMIS Neurosciences Strengthens Global Intellectual Property Portfolioglobenewswire.com - March 11 at 7:00 AMProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conferenceglobenewswire.com - February 22 at 7:00 AMResearchers discover a promising compound to treat neuropathic paininterestingengineering.com - February 4 at 12:20 AMProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccinefinance.yahoo.com - January 22 at 8:48 AMProMIS Neurosciences Inc.: ProMIS Neurosciences, Inc. Announces Leadership Transitionfinanznachrichten.de - January 3 at 9:13 AMBTIG Reaffirms Their Buy Rating on ProMIS Neurosciences (PMN)markets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences Appoints Neil Warma As Interim Chief Executive Officermarkets.businessinsider.com - January 3 at 9:13 AMProMIS Neurosciences, Inc. Announces Leadership Transitionfinance.yahoo.com - January 3 at 9:13 AMProMIS Neurosciences GAAP EPS of -$0.19 beats by $0.14msn.com - November 14 at 7:10 PMProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 3:28 PMProMIS Neurosciences Inc. [PMN] Investment Appeal on the Riseknoxdaily.com - August 23 at 4:58 PMProMIS Neurosciences scales 31% on $20.4M private placementmsn.com - August 22 at 7:40 AMProMIS Neurosciences Announces $20.4 Million Private Placement Financingfinance.yahoo.com - August 21 at 4:38 PMProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlightsfinance.yahoo.com - May 15 at 6:49 PMClosing Bell: Promis Neurosciences Inc down on Friday (PMN)theglobeandmail.com - May 6 at 8:15 AMClosing Bell: Promis Neurosciences Inc up on Thursday (PMN)theglobeandmail.com - April 27 at 10:10 PMData Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Diseasefinance.yahoo.com - April 25 at 5:52 PMProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meetingfinance.yahoo.com - April 24 at 8:50 AMClosing Bell: Promis Neurosciences Inc up on Tuesday (PMN)theglobeandmail.com - April 19 at 1:59 AMClosing Bell: Promis Neurosciences Inc down on Monday (PMN)theglobeandmail.com - April 18 at 3:38 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? April 9, 2024 6:07 AMView Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? Silicon Motion Proves That AI in Motion Stays in MotionApril 16, 2024 11:42 AMView Silicon Motion Proves That AI in Motion Stays in MotionWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?April 22, 2024 6:05 AMView Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?High-Yielding Verizon’s Stock Price Reversal is ImminentApril 22, 2024 8:45 AMView High-Yielding Verizon’s Stock Price Reversal is ImminentAll Headlines Company DescriptionsCanadian Oil SandsTSE:COSCanadian Oil Sands Limited is a Canada-based investment company. The Company owns a 36.74% interest in the Syncrude Joint Venture (Syncrude), a producer of low sulphur, light, synthetic crude oil (SCO). Syncrude is involved in the mining and upgrading of bitumen from oil sands near Fort McMurray in northern Alberta. The Syncrude Project is comprised of open-pit oil sands mines, utilities plants, bitumen extraction plants and an upgrading complex that processes bitumen into SCO. Syncrude's leases are located in the Athabasca oil sands deposit. Syncrude produces SCO by mining oil sands, extracting the bitumen from the sands, upgrading the recovered bitumen into lighter oil fractions and combining those fractions into a single SCO product.First Trust Multi Cap Value AlphaDEX FundNASDAQ:FABThe First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.IntelGenx TechnologiesCVE:IGXIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine. The company's products under development comprise INT0004/2006, an antidepressant; INT0046/2018 for adult use; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid addition; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, and INT0053/2020. The company has licensing, development, and supply agreement with Tilray, Inc. and Gensco Pharma; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.